Alzamend Neuro Partners With Massachusetts General Hospital For First-of-Its-Kind Phase II Study Of AL001 For PTSD Treatment
Portfolio Pulse from Benzinga Newsdesk
Alzamend Neuro has partnered with Massachusetts General Hospital for a Phase II study of AL001 for PTSD treatment. The study will be led by Harvard Associate Professor Dr. Ovidiu Andronesi and will compare AL001 to marketed lithium carbonate in the human brain.
August 19, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alzamend Neuro has announced a partnership with Massachusetts General Hospital for a Phase II study of AL001 for PTSD treatment. The study will be led by Harvard Associate Professor Dr. Ovidiu Andronesi and will compare AL001 to marketed lithium carbonate in the human brain.
The partnership with a prestigious institution like Massachusetts General Hospital and the involvement of a Harvard professor in a Phase II study is a significant milestone for Alzamend Neuro. This could lead to positive sentiment and potential price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100